Jane Street
OVID icon

Jane Street’s Ovid Therapeutics OVID Stock Holding History

Jane Street’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44K Buy
+19,800
New +$35.4K ﹤0.01% 11017

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Jane Street's OVID Position: Q1 2026 in Review

Jane Street reduced its Ovid Therapeutics (OVID) stake by 17% in Q1 2026, selling an estimated $265K and leaving 735,429 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #5470.

Jane Street first reported a position in OVID in Q1 2019 and has held it in 21 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Jane Street held 735,429 shares of Ovid Therapeutics worth $1.63M as of Q1 2026.
  • Jane Street sold 148,438 Ovid Therapeutics shares in Q1 2026, an estimated $265K.
  • Ovid Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5470 holding.
  • Jane Street first reported a position in Ovid Therapeutics in Q1 2019 and has held it in 21 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.